drugset / Trial / NCT01241188

A Trial of the C-Tb Skin Test, When Given Intradermally to Adult Patients Recently Diagnosed With Active Tuberculosis (TB)

NCT01241188 ↗

Phase 2 Completed 253 enrolled Statens Serum Institut
RandomizedParallel-groupQuadruple-blindDiagnostic

Summary

Tuberculosis (TB) continues to be the most important bacterial infection worldwide and therefore new improved diagnostic tests are needed to help doctors in diagnosing TB. The new skin test is named C-Tb. Like the current Tuberculin Skin Test (TST), the C-Tb test is injected just under the skin and will when positive show a redness and/or swelling at the injection site while a negative test will leave no reactions. The aim of this trial is to test the C-Tb skin test in adults diagnosed with TB to determine if a TB infected individual has a truly positive test result (this is called to find the sensitivity of the skin test).

Timeline

Start
2011-04
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject C-Tb Diagnostic / imaging agent 0.1 ug Other
Subject C-Tb Diagnostic / imaging agent 0.1 ml Other
Comparator Tuberculin PPD RT 23 SSI Diagnostic / imaging agent 2 unknown Other

Indications